title: Perspective on dabigatran etexilate dosing: why not follow standard pharmacological principles?
authors.affiliation: Department of Clinical Pharmacology, Christchurch Hospital, 2 Riccarton Avenue, Christchurch 8011, New Zealand. paulc@cdhb.health.nz
authors.forename: Paul K L
authors.initials: PK
authors.lastname: Chin
authors.forename: Jane W A
authors.initials: JW
authors.lastname: Vella-Brincat
authors.forename: Murray L
authors.initials: ML
authors.lastname: Barclay
authors.forename: Evan J
authors.initials: EJ
authors.lastname: Begg
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D001562:Benzimidazoles / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D000069604:Dabigatran; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring / Q000379:methods; D006801:Humans; D007677:Kidney Function Tests; D017410:Practice Guidelines as Topic; D057285:Precision Medicine / Q000379:methods; D011725:Pyridines / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D011725:Pyridines; D000069604:Dabigatran